30 Day FDA Drug Development in Ca...
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 10 Control of Impurities (Organic, Inorganic, Residual Solvents) SUPPLEMENT

Cannabinoid and Psychedelic Pharmacology and Drug Developmen... by Jim Mitchell and Google NotebookLM

Episode notes

This podcast episode explores the fascinating differences between natural botanical extracts and their synthetic counterparts, with a focus on impurities. It delves into how the endocannabinoid system (ECS) interacts with these compounds and introduces the concept of polypharmacy - where multiple compounds work together synergistically. The discussion covers important aspects like variability in natural products, standardization challenges, and safety considerations, while highlighting how these "impurities" might actually be beneficial components that contribute to the overall therapeutic effects.